More Trump drug pricing deals, GSK speeds up development of mRNA flu vaccine, and other biotech news ...

Novartis and Bristol Myers Squibb have paused multiple cell therapy trials, while $480,000 has now become a routine price for ...

The federal spending bill has an important provision for researchers, and Trump announced more MFN deals with pharma firms.

An NIH proposal to cap the number of research grants investigators can receive has drawn a mixed reception, the agency says.

GLP-1 drugs are almost single-handedly forcing employers to reconsider how they pay for their workers’ care.

President Trump on Monday announced the next round of pricing deals with drugmakers, with nine new companies making such agreements.

There has been a wealth of new treatment available” for migraine prevention, said a co-author of new guidelines released ...

With clinical success on a personalized mRNA vaccine for melanoma, experts are hoping for a more stable future for the ...

Caution and survival in radiopharmaceuticals, mRNA skepticism, and more biotech news from The Readout ...

A drug patent case involving Amgen is being closely watched given its potential implications for pharmaceutical patent deals ...

John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. You’re reading the web edition of ...

In today's Pharmalittle newsletter, drug pricing deals, a new cancer therapy approval, and more of the latest pharma ...